dalteparin has been researched along with Right Ventricular Dysfunction in 4 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 5.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
| "There were not differences on pulmonary embolism extension, (P 0." | 2.74 | Improving adjunctive treatment in pulmonary embolism and fibrinolytic therapy. The role of enoxaparin and weight-adjusted unfractionated heparin. ( Archondo, T; Arriaga, R; Bermudez, M; Castillo, F; Comparan-Nuñez, A; Garcia, H; Garcia, J; Garcia-Sosa, A; Garza, A; Gutierrez, J; Hernandez, JM; Jasso, O; Jerjes-Sánchez, C; Martinez, P; Miguel-Canseco, L; Ramírez-Rivera, A; Rangel, F; Reyes, E; Villarreal-Umaña, S, 2009) |
| "Acute pulmonary embolism (APE) causes right ventricular dysfunction (RVD)." | 2.73 | Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism. ( Dai, H; Pang, B; Tong, Z; Wang, C; Wu, Y; Yang, Y; Zhai, Z; Zhu, L, 2008) |
| "We randomized 60 symptomatic pulmonary embolism patients in a 2:1 ratio to 90 days of enoxaparin as monotherapy without warfarin (N=40) or to intravenous unfractionated heparin as a "bridge" to warfarin, target INR 2." | 2.71 | Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. ( Beckman, JA; Dunn, K; Goldhaber, SZ; Sasahara, AA, 2003) |
| "Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 1.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, L | 1 |
| Wang, C | 1 |
| Yang, Y | 1 |
| Wu, Y | 1 |
| Zhai, Z | 1 |
| Dai, H | 1 |
| Pang, B | 1 |
| Tong, Z | 1 |
| Ibrahim, K | 1 |
| Hass, N | 1 |
| Kolschmann, S | 1 |
| Strasser, RH | 1 |
| Braun-Dullaeus, RC | 1 |
| Beckman, JA | 1 |
| Dunn, K | 1 |
| Sasahara, AA | 1 |
| Goldhaber, SZ | 1 |
| Jerjes-Sánchez, C | 1 |
| Villarreal-Umaña, S | 1 |
| Ramírez-Rivera, A | 1 |
| Garcia-Sosa, A | 1 |
| Miguel-Canseco, L | 1 |
| Archondo, T | 1 |
| Reyes, E | 1 |
| Garza, A | 1 |
| Arriaga, R | 1 |
| Castillo, F | 1 |
| Jasso, O | 1 |
| Garcia, H | 1 |
| Bermudez, M | 1 |
| Hernandez, JM | 1 |
| Garcia, J | 1 |
| Martinez, P | 1 |
| Rangel, F | 1 |
| Gutierrez, J | 1 |
| Comparan-Nuñez, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Recombinant Streptokinase and Urokinase in the Treatment of Pulmonary Embolism: A Multi-Center, Randomized Controlled Trial in China[NCT00968929] | Phase 4 | 83 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Efficacy and Safety Evaluation of Low Dosage of Recombinant Tissue Plasminogen Activator (rt-PA) in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China[NCT00781378] | Phase 4 | 118 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| Efficacy and Safety of Body Weight Adjusted Nadroparin vs Standard Unfractionated Heparin for the Initial Treatment of Pulmonary Thromboembolism：a Multi-Centre, Randomised Controlled Trial in China[NCT00796692] | Phase 4 | 274 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| Efficacy and Safety Evaluation of 12-h and 2-h Urokinase Regimes in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China[NCT00799968] | Phase 4 | 129 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| Once Daily Enoxaparin for Outpatient Treatment of Acute Deep Venous Thrombosis and/or Pulmonary Embolism[NCT00413374] | 40 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
| [NCT01956955] | Phase 4 | 150 participants (Anticipated) | Interventional | 2011-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
All-cause mortality (NCT00413374)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Enoxaparin 1.5 mg/kg Once Daily | 0 |
| Enoxaparin 1 mg/kg Twice Daily | 0 |
Major bleeding complication as defined as spinal, retroperitoneal, or intracranial bleeding; drop in hemoglobin ≥2g/dl or transfusion ≥2U or surgical or medical intervention, death related to bleeding. (NCT00413374)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Enoxaparin 1.5 mg/kg Daily | 0 |
| Enoxaparin 1 mg/kg Twice Daily | 3 |
Major clotting complication (recurrent VTE) as defined as recurrent acute pulmonary embolism confirmed on chest CT or recurrent deep vein thrombosis in the contralateral extremity confirmed with venous ultrasound or CT scan while on once daily enoxaparin therapy. (NCT00413374)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Enoxaparin 1.5 mg/kg Daily | 1 |
| Enoxaparin 1 mg/kg Twice Daily | 3 |
3 trials available for dalteparin and Right Ventricular Dysfunction
| Article | Year |
|---|---|
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism.
Topics: Acute Disease; Adult; Aged; Enoxaparin; Feasibility Studies; Female; Hemorrhage; Heparin; Humans; Le | 2003 |
Improving adjunctive treatment in pulmonary embolism and fibrinolytic therapy. The role of enoxaparin and weight-adjusted unfractionated heparin.
Topics: Adult; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Heparin; Hospital Mortal | 2009 |
1 other study available for dalteparin and Right Ventricular Dysfunction
| Article | Year |
|---|---|
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug R | 2008 |